Visual Abstract

ATOS was a 12-month prospective observational study in 18 countries outside US and Western Europe in insulin-naïve adults with T2DM, uncontrolled (HbA1c >7-≤11%) on ≥1 oral antihyperglycemic drug. In this subgroup analysis participants were stratified by BL HbA1c: <8% (N=436), 8-9% (N=1348), 9-10% (N=1351) and ≥10% (N=1287). Age, BMI and duration of diabetes were similar across subgroups (Table). The physician-set individualized HbA1c goal was less stringent in higher BL HbA1c groups. HbA1c target achievement improved over time and were higher in the subgroups with a lower BL HbA1c; >50% of participants with BL HbA1c <9% achieved their target at Month 12. On the other hand, greater reductions in HbA1c, FPG and SMPG were observed in higher vs. lower BL HbA1c subgroups (Table). Increments in the Gla-300 dose were similar across subgroups. Overall, incidences and rates of reported hypoglycemia were low and similar between groups. This subgroup analysis showed that initiation of Gla-300 was effective in reducing HbA1c across BL HbA1c subgroups with benefits of early insulin initiation seen in target achievement in those with lower BL values. Hypoglycemia incidence was low even in the high BL HbA1c subgroups suggesting that further titration can be done with low risk of hypoglycemia thereby enabling more patients to reach their targets.


N. Khan: None. A. Tirosh: Advisory Panel; Self; AstraZeneca, Eli Lilly and Company, Novo Nordisk, Sanofi, Consultant; Self; DreaMed Diabetes, Ltd. H. Vargas-uricoechea: Advisory Panel; Spouse/Partner; Sanofi. M. N. Mabunay: Employee; Self; Sanofi, Stock/Shareholder; Self; Sanofi. M. Coudert: Employee; Self; Sanofi. V. Pilorget: Employee; Self; Sanofi. G. R. Galstyan: None.



Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at